Born in Scotland, Dr. Ashley graduated with first class Honors in Physiology and Medicine from the University of Glasgow. He completed medical residency and a PhD in molecular physiology at the University of Oxford before moving to Stanford University where he trained in cardiology and advanced heart failure, joining the faculty in 2006. His group is focused on precision medicine. In 2010, he led the team that carried out the first clinical interpretation of a human genome. The paper published in the Lancet was the focus of over 300 news stories, became one of the most cited articles in clinical medicine that year, and was featured in the Genome Exhibition at the Smithsonian in DC. The team extended the approach in 2011 to a family of four and now routinely applies genome sequencing to the diagnosis of patients at Stanford hospital where Dr Ashley directs the Clinical Genome Service and the Center for Inherited Cardiovascular Disease. In 2014, Dr Ashley became co-chair of the steering committee of the NIH Undiagnosed Diseases Network. In 2013, Dr Ashley was recognized by the White House Office of Science and Technology Policy for his contributions to Personalized Medicine. He is recipient of the National Innovation Award from the American Heart Association as well as an NIH Director’s New Innovator Award. He works with many Silicon Valley companies and investors. He is Principal Investigator of the MyHeart Counts cardiovascular health study, launched in collaboration with Apple in 2015. In 2016, he was part of the winning team of the $75m One Brave Idea competition funded by Google, the AHA and Astra Zeneca. Father to three young Americans, in his "spare" time, he tries to understand American football, plays the saxophone in a jazz quartet, and conducts research on the health benefits of single malt Scotch whisky.